Tag Directory / DRUGDEVELOPMENT     showing 41–60 of 84


BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing / MedCity

Frank Vinluan / medcitynews - Infigratinib achieved statistically significant improvement in growth rate and body composition in a Phase 3 clinical trial that tested the BridgeBio Pharma drug in achondroplasia, the most common form of dwarfism. Regulatory submissions are planned for l…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda

BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing

26 days / medcitynews / Frank Vinluan

BridgeBio's dwarfism drug succeeds in Phase 3, adding to recent late-stage wins

27 days / endpoints / Max Gelman

Saturday, February 14, 2026, 12:22 am / permalink 19171 / 2 stories in 25 days


FDA refuses to review Moderna flu vaccine / Beckers

Ella Jeffries / beckershospitalreview - Moderna has received a refusal-to-file letter from the FDA’s Center for Biologics Evaluation and Research for its biologics license application for mRNA-1010, its investigational seasonal influenza vaccine. The letter, signed by Vinayak Prasad, MD, chief …

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda

Moderna's flu shot dilemma muddies 2028 break-even guidance

26 days / endpoints / Max Bayer

The Old System Failed Patients. Change Must Go Further and Faster – Garo Armen

26 days / oncodaily

PTC Therapeutics withdraws US filing for troubled Duchenne treatment Translarna

26 days / endpoints / Ayisha Sharma

FDA rejects Moderna's mRNA flu vaccine application, for reasons with no basis in the law

26 days / medicalxpress

What the Health? From KFF Health News: New Flu Vax? FDA Says No Thanks

26 days / kffhealthnews

Controversy around FDA’s Prasad rises again after Moderna rejection, behavior allegations

27 days / endpoints / Zachary Brennan

Jeff Coller: The FDA Just Refused to Review Moderna’s mRNA Influenza Vaccine Application

27 days / oncodaily

FDA may consider Moderna's flu vaccine in a narrower group

27 days / endpoints / Max Bayer

U.S. Health Officials Defend Rejection of Moderna’s Flu Vaccine

27 days / nytimes / Christina Jewett

Moderna Says FDA Refusal to Review mRNA Flu Vaccine Contradicts Federal Rules, Prior Guidance

27 days / medcitynews / Frank Vinluan

Prasad overruled vaccine review team, office director on Moderna flu shot

28 days / endpoints / Zachary Brennan

FDA refuses to review Moderna flu vaccine

28 days / beckershospitalreview / Ella Jeffries

FDA refuses to review Moderna’s mRNA flu vaccine

28 days / healthcaredive / Delilah Alvarado

F.D.A. Refuses to Review Moderna Flu Vaccine

28 days / nytimes / Christina Jewett and Rebecca Robbins

Moderna accuses FDA of shifting standard as agency refuses flu shot review

28 days / endpoints / Max Bayer

Wednesday, February 11, 2026, 10:25 am / permalink 19026 / 15 stories in 28 days


AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelo / Endpoints

Anna Brown / endpoints - The FDA has handed AstraZeneca a complete response letter for the subcutaneous prefilled, self-injectable pen of Saphnelo for systemic lupus erythematosus (SLE), a month after the asset gained approval in Europe ...

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda

Former AstraZeneca senior staff charged with illegal trade in China

27 days / endpoints / Nicole DeFeudis

Moderna says FDA refuses its application for new mRNA flu vaccine

28 days / medicalxpress

FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

28 days / oncodaily

FDA delays approval of AstraZeneca’s injectable lupus drug

5 wks / beckershospitalreview / Ella Jeffries

AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelo

5 wks / endpoints / Anna Brown

Monday, February 9, 2026, 12:21 am / permalink 18917 / 5 stories in 4 wks


World Cancer Day: A Global Call to Awareness and Action 2026, Part 2 / OncoDaily

oncodaily - World Cancer Day is observed annually on February 4 and was established in 2000 at the World Summit Against Cancer for the New Millennium in Paris. The initiative was led […]

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment


Early Detection & Access Initiatives

Jérôme Salomon: A New Analysis by WHO and IARC on Cancer Prevention

4 wks / oncodaily

Michelle Mitchell: The National Cancer Plan Must Deliver for People Affected by Cancer

4 wks / oncodaily

Gonzalo López-Cuevas: Workers in Mexico City Can Access Paid Days for Early Detection Tests Covering Up to Six types of Cancer

4 wks / oncodaily

Efforts to Close Cancer Screening Gap – Singapore Cancer Society

4 wks / oncodaily


Other Cancer News

Oncology This Week: OncoDaily Weekly Feb 2-8, 2026

4 wks / oncodaily

Andreas Charalambous: Preparing the Workforce for the Future

4 wks / oncodaily

Muna Al-Khaifi: A Breast Cancer Survivorship-Led Art Workshop for Undergraduate Medical Students

4 wks / oncodaily

Creating an Interest Group Focused on Hematological Malignancies in Older Adults – SIOG

4 wks / oncodaily

Nihanthy Sreenath: Presenting a Research at Binaytara Conference on Cancer Health Disparities

4 wks / oncodaily

Sylvester’s Kenneth C. Griffin Cancer Research Building Welcomes the Next Era of Cancer Research

4 wks / oncodaily

Nicholas DeVito: CRUSH Colorectal Cancer 5K is Just Over a Month Away!

4 wks / oncodaily

Kleida Mati: Selected for 2026 International Development and Education (IDEA) Award

4 wks / oncodaily

Jasmine Kamboj: Grateful to Attend Global OncoThon With Ruiling Yuan

4 wks / oncodaily

Amal Al Omari: From Cairo to Doha

4 wks / oncodaily

Robert Olson: A Small Northern Cancer Centre with a Global Presence in The Lancet Oncology

4 wks / oncodaily

Julie Gralow: Inaugural Meeting of AMSTRO in Dubai

4 wks / oncodaily

Giannis Mountzios: The Most Successful ITCD 2026 is Officially Over in the Best Way

4 wks / oncodaily

Looking to the Future with the Launch of a Second FERO-Aladina Scholarship – Fundación Aladina

4 wks / oncodaily

US layoffs in January hit highest monthly record since 2009

4 wks / semafor / Rohan Goswami


Research and Treatment Advances

Savio Domenico Pandolfo: What We’ve Learned About Complex RCC Surgery

4 wks / oncodaily

Naoto T. Ueno: How Payload Choice Can Extend Clinical Benefit in Breast Cancer

4 wks / oncodaily

Sanam Loghavi and Farhad Ravandi: Unlocking Germline Predisposition in AML Beyond Somatic Mutations

4 wks / oncodaily

Jianjiao Ni: Local Consolidative Therapy as a Precision Strategy in IV NSCLC, with Eric K. Singhi and Kyle G. Mitchell

4 wks / oncodaily

Petros Grivas: Opening a New Option for Patients With Anti-PD-1 Resistant Urothelial Cancer

4 wks / oncodaily

Pat Soon-Shiong: An Urgent Warning From JAMA on Lymphopenia and Cancer

4 wks / oncodaily

Registrations Open for Clinical Trial Statistics for Non-Statisticians Course – EORTC

4 wks / oncodaily

Pre-Conference Workshop on Guideline-Based Oncology Acupuncture – Society for Integrative Oncology

4 wks / oncodaily

Ciarán Nicholl: New Factsheet on the Estimated Cancer Burden in 2024

4 wks / oncodaily

Megan Melody: New Article Evaluates the Structure of Hematology/Oncology Fellowship Curricula Across the USA

4 wks / oncodaily

Rui Medeiros: HPV and Cancer: The European Approach at 10th Hellenic Cancer Federation | ELLOK Conference

4 wks / oncodaily

Constantinos Zambirinis: How CCL3-Producing Aged Neutrophils Promote Tumor Growth Across Cancers

4 wks / oncodaily

Bishal Gyawali: Letter to the Editor and Response Published in The Lancet Oncology

4 wks / oncodaily

Bruce Levine: How Tumor-Brain Crosstalk Suppresses Cancer Immunity

4 wks / oncodaily

Jianjiao Ni and Estela Rodriguez: Key Insights Improving NSCLC Care from the 2026 ASCO Guidelines

4 wks / oncodaily

Al-Ola A Abdallah: Teclistamab and Daratumumab in Relapsed Myeloma

4 wks / oncodaily

Sumanta Pal and Atul Batra: How the PLANET Study Is Driving Better TNBC Treatment Around the World

4 wks / oncodaily

Stephanie A. Haddad: Presenting Our Real-World Correlation Analysis at the Mays Cancer Center

4 wks / oncodaily

Why Cure Rates Are Rarely Used in Metastatic Cancer

4 wks / oncodaily

What Does Remission Mean in Pancreatic Cancer?

4 wks / oncodaily

When Surgery Is Not an Option: Pancreatic Cancer Treatment Choices

4 wks / oncodaily

Lazar Popovic: VANESSA Brings Clarity to PD-L1 Outcomes in Real-World Triple-Negative Breast Cancer

4 wks / oncodaily

Jeremy Bellaiche: I am Humbled to Collaborate With an Expert Like Professor Arjun K Ghosh

4 wks / oncodaily

Danny Burke: Comprehensive Overview of the Global Cancer Crisis

4 wks / oncodaily

Joshua Omale: We Collect Cancer Data, But Fail to Move It

4 wks / oncodaily

Azza Sarfraz: Outstanding and Highly Informative Talk by Dr. Sarbajit Mukherjee

4 wks / oncodaily

Vivek Subbiah: Thrilled to Share Our Latest Paper in npj Precision Oncology

4 wks / oncodaily

Dual pancreatic carcinomas: clonally related or independent primaries?

4 wks / nature


World Cancer Day Global Events

Neeraj Agarwal: Celebrating ASCO Leadership and The Global Impact on Cancer Care

4 wks / oncodaily

Neeraj Agarwal: ASCO Leadership Gathers at Headquarters on World Cancer Day

4 wks / oncodaily

Miriam Mutebi: When Cancer Care Breaks Down Silos – Historic World Cancer Day Gathering in Botswana

4 wks / oncodaily

World Cancer Day: A Global Call to Awareness and Action 2026, Part 2

4 wks / oncodaily


All Other Stories

Tanja Spanic: Showing Up Quietly to Improve Life for People Facing Cancer

25 days / oncodaily

Complete remission of relapsed ATXN2L::JAK2 fusion positive anaplastic large cell lymphoma following ruxolitinib monotherapy in a child

25 days / nature

What telehealth changes for adult survivors of childhood cancers: More genetic testing, earlier screening options

25 days / medicalxpress

The 'zombie cell' effect: New study explains chemotherapy resistance in lung and ovarian cancers

25 days / medicalxpress

Erika Hamilton: How Skip Burris Brought Community and Compassion to Cancer Research

25 days / oncodaily

Myeloma Paper of the Day, January 13th, Suggested by Robert Orlowski

25 days / oncodaily

Felicia Marie Knaul: New Study on Unequal Access to Paediatric Palliative Care

25 days / oncodaily

Steven Kridel and Yusuke Shiozawa: New Leadership for the Cancer Biology PhD Program

25 days / oncodaily

Kamal S. Saini: How Much Alcohol Is Too Much? New Data on Breast Cancer Risk

25 days / oncodaily

Vivek Subbiah: Growing Challenges and Biology of Lung Cancer in Never Smokers

25 days / oncodaily

Omnia Korani: Chairing AYA vs Senior Adult Supportive and Survivorship Session at 17th Assiut Clinical Oncology Conference

25 days / oncodaily

Study identifies a new class of drug targets for aggressive leukemia

25 days / medicalxpress

Miriam Mutebi: Two Messages That Reminded Me Exactly Why We Do This Work

25 days / oncodaily

Joanna Metzner-Sadurski: Teaching, Mentorship and Celebrating Student Achievement

25 days / oncodaily

New Research to Predict Immunotherapy Response in Head and Neck CSCC – Peter MacCallum Cancer Centre

25 days / oncodaily

Daniel Stover: Honored to Join Julie McMahon at 2026 Komen Health Equity Summit

25 days / oncodaily

Navneet Majhail Appointed President of FACT Board of Directors – Sarah Cannon Cancer Network

25 days / oncodaily

Cell and gene therapy across 35 years—a bibliometric analysis of global advances

26 days / medicalxpress

Nicola Fusco: Launching ‘BIANCA,’ First AI-Driven Digital Biobank

26 days / oncodaily

Aleix Prat: New Article on HER2DX Validation in Advanced HER2-Positive Breast Cancer

26 days / oncodaily

2026 Nursing Program With Case-Based Learning and Expert Discussions – NCCN

26 days / oncodaily

Benjamin L. Ebert Celebrates the Spirit of the Pan-Mass Challenge Winter Cycle

26 days / oncodaily

Colorectal cancer is increasing among young people, James Van Der Beek's death reminds

26 days / medicalxpress

Rob Pieters: Supporting Poland’s Journey Toward Centralized Childhood Cancer Care

26 days / oncodaily

Bernard A. Fox: What Comes Next for TCR-T and Adoptive Cell Therapy

26 days / oncodaily

ICCD 2026 Showcasing Impact, Renewing Commitment – Childhood Cancer International

26 days / oncodaily

Carolina Paula Bañuelos: Insights from DNA Damage Biology with Clinical Implications

26 days / oncodaily

Zainab Shinkafi-Bagudu: How We Can Make Cancer Care More Patient-Centred In Our Communities

26 days / oncodaily

A Defining Moment for Cancer Care in Our Region – Dana-Farber Cancer Institute

26 days / oncodaily

Amy C. Moore and Roland Matthews: When Professional Excellence Meets Personal Grace

26 days / oncodaily

EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Chloride

26 days / esmo

Insights from the PREOPANC-2 Trial: Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer

26 days / oncodaily

Remembering James Van Der Beek and Raising Awareness for CRC – Colorectal Cancer Alliance

26 days / oncodaily

Pancreatic cancer: Warning signs to heed

26 days / medicalxpress

Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma

26 days / nature

Researchers develop metastasis prevention therapy based on glycan targeting

26 days / medicalxpress

Colorectal cancer is rising in younger adults. Here's who is most at risk and symptoms to watch for

26 days / medicalxpress

Brigham and Women’s to phase out Dana-Farber PAs: Boston Globe

26 days / beckershospitalreview / Elizabeth Gregerson

States ranked by projected growth in new cancer cases: 2026

26 days / beckershospitalreview / Erica Cerutti

New characteristics of aggressive prostate cancer identified

26 days / medicalxpress

2026 ESO College Mentorship Pairings

26 days / oncodaily

Abdu Adem Yesufe: Significance of ISO Accreditation for ONCO Pathology and National Healthcare

26 days / oncodaily

Caring Beyond Cure in African Cancer Care Explored by Christian Ntizimira – ACREOL Global

26 days / oncodaily

Innovation Makes Prostate Cancer Screening Faster, More Accessible – NCI Kenya

26 days / oncodaily

Howard McLeod: How Radioligand Therapy Influences Clonal Hematopoiesis in Prostate Cancer

26 days / oncodaily

Genetic risk may rival obesity as a key driver of endometrial cancer

26 days / medicalxpress

Best diagnostic test for ovarian cancer in premenopausal women identified

26 days / medicalxpress

Michael McNeil and Ondrej Vlcek Advance Global Pediatric Palliative Care Education in Prague

26 days / oncodaily

Is Colorectal Cancer Treatment Moving in the Wrong Direction for Adults Under 50?

26 days / oncodaily

US and India Move Toward a New Era of Oncology Drugs Security

26 days / oncodaily

Rallying more T-cells to immunotherapy's fight against cancer

26 days / medicalxpress

Lung cancer drug offers a surprising new treatment against ovarian cancer

26 days / medicalxpress

Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer

26 days / medicalxpress

Rahul Bhargava: Why Holding Back Effective Myeloma Therapy Fails Patients

26 days / oncodaily

John Hennessy: Why Evidence-Based Care Remains Uneven in Bladder Cancer

26 days / oncodaily

Another win for GLP-1s and cancer risk: 5 study notes

26 days / beckershospitalreview / Elizabeth Gregerson

Cancer cell study sheds light on cachexia's origins

26 days / medicalxpress

George Coukos Brings Cell Therapy Research Leadership – Weill Cornell Medicine

26 days / oncodaily

Study strengthens evidence supporting lung-sparing surgery, offering hope for mesothelioma patients

26 days / medicalxpress

PANOVA-3 Leads to FDA Approval of Optune Pax in Locally Advanced Pancreatic Cancer

26 days / oncodaily

Thomas Sutherland Brings Pediatric Cancer Research from the Lab to the Showcase Stage

26 days / oncodaily

Unraveling the mystery of why some cancer treatments stop working

26 days / medicalxpress

FDA clears 1st new treatment in 30 years for pancreatic cancer

27 days / beckershospitalreview / Ella Jeffries

A pancreatic cancer approval; Seres cuts staff

27 days / endpoints / ENDPOINTS

KESHO: United by Unique, The Kenyan Perspective

27 days / oncodaily

Why Prevention and Early Detection Matter More Than Ever – American Cancer Society

27 days / oncodaily

When Distance Stands Between a Child and Care – World Child Cancer

27 days / oncodaily

Reaffirming Commitment to Compassionate Cancer Care on World Cancer Day – Qatar Cancer Society

28 days / oncodaily

Amar Rewari: Policy Still Needs to Catch Up With the Progress in Cancer Care

28 days / oncodaily

Investigators study ivermectin's 'ability to kill cancer cells'

28 days / medicalxpress

First Expert Workshop to Kick off Third EU Cancer Screening Report – IARC

28 days / oncodaily

Research careers – what you need to lead

28 days / cancerresearchuk / Cancer Research UK

George Calin: New Findings on β-Adrenergic Signaling in TP53-Mutant Oral Squamous Cell Carcinoma

28 days / oncodaily

Julie S. Torode: Reflections on CEO Tenure and Leadership Transition in Cancer Nonprofits

28 days / oncodaily

Paolo Tarantino: New Article on HER2DX Genomic Test in HER2-Positive Metastatic Breast Cancer

28 days / oncodaily

Hind Rafei: Thanks DoD Ovarian Cancer Research Program for Support

28 days / oncodaily

Stephanie A. Haddad: Our Abstract on Fertility Preservation for AYA Patients Published in IJCCD

28 days / oncodaily

Phase 2 ABACO Trial Updates: Cabozantinib In Pretreated Metastatic Colorectal Cancer

28 days / oncodaily

DNA barcoding reveals the complexity of breast cancer liquid biopsies

28 days / medicalxpress

Sushmita Sen: Key Discussions at CDDF Annual Conference on Clinical Trials and Patient-Centered Research

28 days / oncodaily

Accelerator Startup Cohort 2026 at Moffitt Cancer Center – CancerX

29 days / oncodaily

Nita Radhakrishnan: IPA Session on Pediatric Oncological Emergencies for International Childhood Cancer Day

29 days / oncodaily

Chris Chukwunyere: Pink Blue Cancer Walk in Abuja

29 days / oncodaily

The Max Foundation: One Word That Represents Your Voice in The Fight Against Cancer

29 days / oncodaily

Train at NCI: Applications For the Fall 2026 iCURE Cohort Are Closing Soon

29 days / oncodaily

Rita A. Sakr: Great Privilege to Be Part of First SSMC Women’s Cancer Forum

29 days / oncodaily

Aharon Tsaturyan: Curative Radiotherapy for Pancreatic Cancer – Applying International Standards in Armenia

29 days / oncodaily

Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours

29 days / esmo

Hesham ElGhazaly: Sustainable progress in cancer care is never achieved in isolation – Together, The Sky is the limit

29 days / oncodaily

Survivorship Doesn’t End When Treatment Does: Colette’s Story Shows Why – World Child Cancer

29 days / oncodaily

Kevin King: City of Hope – Expanding Oncology Programs and Speed to Care in Chicago

29 days / oncodaily

Chris Jones: Research Training in Radiation Oncology – Global Pathways, Barriers and Enablers

29 days / oncodaily

Asim Belgaumi: Visiting PAEC’s NORI Center as Part of GPACCM to Advance Childhood Cancer Care

29 days / oncodaily

Mikita Rudzishkin: Grateful to ESO for Supporting Oncologists on Their Lifelong Educational Journey

29 days / oncodaily

Elad Sharon: Exploring the Side Effects of Immune Checkpoint Inhibitors

29 days / oncodaily

Assessments of social vulnerability on central nervous system cancer disparities in the United States

29 days / nature

Peripheral blood CD14 + monocytes in luminal breast carcinoma subtypes: in preliminary research and overview of candidate biomarker proteins

29 days / nature

Association of 25-hydroxyvitamin D levels and vitamin D receptor gene polymorphisms with breast cancer risk in Bangladeshi women

29 days / nature

The state of imaging glycolytic metabolism in cancer with magnetic resonance

29 days / nature

Ruthresh Rao Subramanyan: Translating Advocacy Into a Measurable Impact

4 wks / oncodaily

Ruthresh Rao Subramanyan: National Cancer Society Malaysia Hosted Two Executive Forums

4 wks / oncodaily

Christos Tsagkaris: ELLOK 10th Anniversary at World Cancer Day 2026

4 wks / oncodaily

Nirmala Bhoo Pathy: Mentorship, Growth and Connections at 14th Asia-Pacific Breast Cancer Summit 2026

4 wks / oncodaily

Douglas Flora: AI in Precision Oncology Call For Papers for our April and June issues

4 wks / oncodaily

Ravindran Kanesvaran Discusses Singapore’s Widening Cancer Screening Gap on MONEY FM 89.3 – NCCS

4 wks / oncodaily

NCI Awards Five-Year R50 Research Specialist Award to Marie Wood – CU Anschutz Department of Medicine

4 wks / oncodaily

Noha Soror: World Cancer Day ASCO Webinar Brings Global Oncology Leaders Together

4 wks / oncodaily

Eftychia Tataridou: World Cancer Day Scientific Meeting “The Circle of Care” Focuses on Prevention, Early Diagnosis, and Holistic Cancer Care

4 wks / oncodaily

Lilly returns to Innovent to partner on cancer and immune diseases

4 wks / endpoints / Lei Lei Wu

Why Colorectal Cancer Rates are Rising in Younger People – Cancer Grand Challenges

4 wks / oncodaily

PFDN2 stabilizes PYCR2 to activate Wnt/β-catenin signaling and promote colorectal cancer progression

4 wks / nature

Saturday, February 7, 2026, 3:21 pm / permalink 18896 / 162 stories in 4 wks


#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial / Endpoints

Ayisha Sharma / endpoints - Bayer shared more details from its unexpected win in a Phase 3 study testing its next-generation blood thinner for secondary stroke prevention. The factor XIa inhibitor, named asundexian, reduced the occurrence of ischemic stroke by ...

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Bayer Reveals Data That Could Make Stroke Prevention Drug Its Next Blockbuster Product

4 wks / medcitynews / Frank Vinluan

#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial

4 wks / endpoints / Ayisha Sharma

Saturday, February 7, 2026, 3:21 am / permalink 18873 / 2 stories in 4 wks


Eikon Therapeutics Raises $381 M in IPO to Advance Live-Cell Imaging in Cancer Drug Discovery / OncoDaily

oncodaily - Eikon Therapeutics has raised $381 million through its IPO, pricing at the top of its range in a strong sign of renewed investor appetite for biotech offerings. The South San […]

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Eikon Therapeutics Raises $381 M in IPO to Advance Live-Cell Imaging in Cancer Drug Discovery

4 wks / oncodaily

Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials

4 wks / medcitynews / Frank Vinluan

Saturday, February 7, 2026, 1:21 am / permalink 18871 / 2 stories in 4 wks


Novo Nordisk vows legal action to protect Wegovy pill / Medical Express

medicalxpress - Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.

#obesity #healthcare #pharmaceuticals #drugpricing #novonordisk #weightloss #drugdevelopment #digitalhealth

Novo Nordisk to expand Irish factory for Wegovy pill

26 days / endpoints / Anna Brown

Blockbuster weight loss drugs like Ozempic deliver big results but face big questions

28 days / sciencedaily

Why people won't quit a weight loss drug, even when it makes them feel sick

28 days / medicalxpress

FDA to Novo Nordisk: Correct ‘misleading’ GLP-1 pill TV ad

28 days / beckershospitalreview / Erica Cerutti

The fallout from Novo vs. Hims

29 days / endpoints / Lydia Ramsey Pflanzer

Hims pulls cheaper Wegovy pill after federal scrutiny

29 days / medicalxpress

Hims retreats from weight loss pill launch as Novo, FDA pressure mounts

4 wks / fiercehealthcare

After industry pressure, Hims & Hers stops selling Wegovy pill

4 wks / beckershospitalreview / Paige Twenter

Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages

4 wks / endpoints / Elizabeth Cairns

'Weight-loss jab helped me find my cancer'

4 wks / bbc

Hims & Hers Withdraws Knockoff Weight-Loss Pill After Regulatory Scrutiny

4 wks / nytimes / Rebecca Robbins

Hims says it will stop selling GLP-1 pill, after legal pressure from US

4 wks / endpoints / Drew Armstrong

The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more

4 wks / endpoints / Max Gelman

US calls for DOJ investigation of Hims over GLP-1 drugs

4 wks / endpoints / Shelby Livingston

Synergizing global clinical trials data: GLP-1 receptor agonist safety and novel clinical applications

4 wks / medicalxpress

FDA's Makary pledges crackdown on mass marketing of 'illegal copycat drugs' in wake of Hims' Wegovy pill push

4 wks / fiercehealthcare

FDA chief Makary takes aim at Hims' compounded Wegovy pill plans

4 wks / endpoints / Max Bayer

Novo's threat to sue Hims over Wegovy pill faces legal hurdle

4 wks / endpoints / Shelby Livingston

War breaks out over GLP-1 pills

4 wks / beckershospitalreview / Paige Twenter

Novo Nordisk vows legal action to protect Wegovy pill

4 wks / medicalxpress

Him & Hers plans to offer cheaper version of Wegovy pill, prompting Novo Nordisk to threaten legal action

4 wks / fiercehealthcare

Telehealth provider Hims goes after Novo's weight-loss pill with compounded version

4 wks / endpoints / Zachary Brennan

Thursday, February 5, 2026, 3:23 pm / permalink 18807 / 22 stories in 4 wks


Letters, Jan. 27, 2026: ‘A Team Canada must be assembled’ to help diversify trade / Calgary Sun

Jeffrey Morgan / calgarysun - Need to diversify I just watched a video detailing the prior commercial trading practices between Canada and the U.S. It makes me realize there is nothing more important than Canada diversifying its trade with other countries. By ‘nothing,’ I mean all pro…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda

STS: Assessment of more than one nodal station tied to increased upstaging, survival in NSCLC

4 wks / medicalxpress

Jad Chahoud: Why Timing of Immunochemotherapy Matters in Lung Cancer

4 wks / oncodaily

Giannis Mountzios: What happens to patients with st3 unresectable NSCLC who never receive maintenance IO?

5 wks / oncodaily

Cordyceps sinensis enhances the efficacy of anti-PD-1 immunotherapy in Lewis lung adenocarcinoma

5 wks / nature

Therapeutic potential of targeting MASTL in lung adenocarcinoma

5 wks / nature

First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial

5 wks / nature

Narjust Florez: Global Advances and Strategic Priorities in Lung Cancer Care

5 wks / oncodaily

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutated NSCLC After TKI Therapy

5 wks / oncodaily

Letters, Jan. 27, 2026: ‘A Team Canada must be assembled’ to help diversify trade

6 wks / calgarysun / Jeffrey Morgan

Saturday, January 31, 2026, 2:22 pm / permalink 18622 / 9 stories in 5 wks


FDA lifts hold on one of two Phase 3 gene editing studies by Intellia / Endpoints

Lei Lei Wu / endpoints - The FDA has allowed Intellia Therapeutics to resume one of its two pivotal trials of a gene editing therapy for transthyretin amyloidosis, which is a disease caused by misfolded proteins. Intellia

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

Gene-editing therapy proves effective for Leber's hereditary optic neuropathy

4 wks / medicalxpress

China startup AccurEdit raises $75M for gene editing therapies

5 wks / endpoints / Ryan Cross

FDA lifts hold on one of two Phase 3 gene editing studies by Intellia

6 wks / endpoints / Lei Lei Wu

FDA lifts hold on Intellia’s phase 3 trial for genetic nerve disease

6 wks / beckershospitalreview / Ella Jeffries

Saturday, January 31, 2026, 7:22 am / permalink 18610 / 4 stories in 5 wks


#JPM26: Day 3 at the JP Morgan Healthcare Conference / Endpoints

ENDPOINTS / endpoints - It’s Wednesday at the JP Morgan Healthcare Conference, and as the sessions wind down, we’ll be keeping an eye on presentations from WuXi AppTec and AbbVie. Yesterday afternoon, our Executive Editor Drew Armstrong spoke with ...

#obesity #healthcare #pharmaceuticals #weightloss #biotech #drugdevelopment #digitalhealth

What if Oprah Knew About Fractyl Health?

5 wks / medcitynews / Arundhati Parmar

Which Digital Health Startups Will Win in 2026?

6 wks / medcitynews / Katie Adams

CMS picks Lilly’s Trulicity for third round of Medicare negotiations

6 wks / endpoints / Nicole DeFeudis

The future GLP-1 might be a gene therapy: Report

6 wks / beckershospitalreview / Paige Twenter

Vivek Subbiah: AI-Driven Screening Opens New Era in Drug Discovery

6 wks / oncodaily

David K. Lee: What’s Ahead for Servier in 2026 – Strengthening Our Pipeline, Expanding Our Impact

6 wks / oncodaily

Industry Voices—Micro-app strategy can lead to macro improvements

6 wks / fiercehealthcare

Five Collaboration Trends That Shaped Healthcare AI in 2025

6 wks / medcitynews / Marva Bailer

How Bessemer Sees 2026 Shaping Up as Healthcare AI’s Breakout Year

6 wks / medcitynews / Katie Adams

#JPM26: Hua Medicine plots diabetes drug expansion in China and beyond

6 wks / endpoints / Jared Whitlock

Viewpoint: What Taylor Swift and JPM2026 can teach us about the ‘next era’ of healthcare

6 wks / beckershospitalreview / Mackenzie Bean

Walid Kamoun: Closing J.P. Morgan with Our AI Partnership Expedition

6 wks / oncodaily

Bristol Myers Squibb, Microsoft partner on AI lung cancer detection

6 wks / beckershospitalreview / Ella Jeffries

Bristol Myers Squibb Announces Collaboration with Microsoft to Accelerate the Early Detection of Lung Cancer

7 wks / oncodaily

#JPM26: Regeneron, Lilly, Summit on rivals crowding into same targets

7 wks / endpoints / Andrew Dunn

J&J, Isomorphic sign research deal for AI-made molecules

7 wks / endpoints / Andrew Dunn

GSK makes $2.2B deal for RAPT and its food allergy candidate

7 wks / endpoints / Kyle LaHucik

JPM Deals Recap: Boston Scientific Acquisition, a Mega Round for Parabalis, Enodia Emerges & More

7 wks / medcitynews / Frank Vinluan

10 Key MedTech Themes for 2026

7 wks / medcitynews / Vinita Kailasanath, Kayla Weston, Yungjee Kim and Shannon O’Hara

Bill Gates: AI Innovations Must Reach the People Who Need Them Most

7 wks / oncodaily

Zhaohui Su: Federated Learning With Differential Privacy Balances Accuracy and Patient Data Protection

7 wks / oncodaily

Zhaohui Su: AI, Decentralization, and the Evolution of Clinical Trials

7 wks / oncodaily

Proud to Have Renee Gala Represent at the 44th J.P. Morgan Healthcare Conference – Jazz Pharmaceuticals

7 wks / oncodaily

Zhen Su: Unlocking the Full Potential of Invika as a Next-Generation Immuno-Oncology Backbone

7 wks / oncodaily

#JPM26: Day 3 at the JP Morgan Healthcare Conference

1 month / endpoints / ENDPOINTS

#JPM26: Q&A with Bristol Myers Squibb CEO Chris Boerner on 2026 outlook

1 month / endpoints / Andrew Dunn

#JPM26: Novo Nordisk CEO says pharma can learn from the GLP-1 compounding boom

1 month / endpoints / Ngai Yeung

JPM26: Elation Health embeds Anthropic's Claude into EHR to power chart summaries

1 month / fiercehealthcare

Saturday, January 17, 2026, 7:21 pm / permalink 18138 / 28 stories in 7 wks


F.D.A. Decisions on Abortion Pill Were Based on Science, New Analysis Finds / NYT

Pam Belluck / nytimes - A study of more than 5,000 pages of agency documents on mifepristone over 12 years found that agency leaders almost always followed the evidence-based recommendations of scientists.

#healthcare #pharmaceuticals #publichealth #governmentpolicy #drugdevelopment #fda

Why medication abortion is the top target for anti-abortion groups in 2026

5 wks / medicalxpress

FDA asks court to pause Louisiana's abortion pill fight

5 wks / endpoints / Max Bayer

Why Medication Abortion Is the Top Target for Anti-Abortion Groups in 2026

6 wks / kffhealthnews / Julie Rovner, KFF Health News

Study finds FDA used evidence, not politics, in abortion pill decisions

1 month / medicalxpress

F.D.A. Decisions on Abortion Pill Were Based on Science, New Analysis Finds

1 month / nytimes / Pam Belluck

Saturday, January 17, 2026, 8:21 am / permalink 18126 / 5 stories in 7 wks


FDA rejects cancer therapy for rare post-transplant disease / Beckers

Ella Jeffries / beckershospitalreview - Atara Biotherapeutics received a second complete response letter from the FDA for its biologics license application for Ebvallo (tabelecleucel). The letter, received Jan. 9, said the FDA no longer considers the single-arm ALLELE trial adequate to support …

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda

FDA rejects cancer therapy for rare post-transplant disease

1 month / beckershospitalreview / Ella Jeffries

FDA again rejects Atara, Pierre Fabre's cell therapy for Epstein-Barr virus

1 month / endpoints / Max Gelman

Friday, January 16, 2026, 11:55 am / permalink 18057 / 2 stories in 7 wks


NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery / OncoDaily

oncodaily - Dave Ricks, Chair, CEO at Eli Lilly and Company, shared Eli Lilly and Company‘s post on LinkedIn, adding: “Exciting news from the JPMorgan Healthcare Conference: Lilly and NVIDIA are joining […]

#healthcare #pharmaceuticals #elililly #publichealth #biotech #drugdevelopment

NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery

7 wks / oncodaily

Eli Lilly, Nvidia sign five-year, up to $1B deal for AI laboratory

1 month / endpoints / Andrew Dunn

Thursday, January 15, 2026, 1:23 pm / permalink 17925 / 2 stories in 7 wks


Merck Could Strike 30 Billion Deal for Revolution Medicines / OncoDaily

oncodaily - According to the Financial Times, Merck is in talks to acquire Revolution Medicines, a Redwood City, California-based cancer drug developer, in a deal that could value the company at roughly […]

#healthcare #pharmaceuticals #publichealth #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Merck Could Strike 30 Billion Deal for Revolution Medicines

1 month / oncodaily

Speculation builds about a deal for Revolution Medicines

2 months / endpoints / Kyle LaHucik

Monday, January 12, 2026, 1:21 am / permalink 17767 / 2 stories in 1 month


Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals / MedCity

Frank Vinluan / medcitynews - Aktis Oncology’s IPO will support a pipeline of “miniprotein” radioconjugates that could offer advantages over other targeted radiation cancer treatments. In addition to its internal pipeline, Aktis has a discovery partnership with Eli Lilly. The post Akt…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Novartis licenses radiopharma asset from Chinese biotech for $50M upfront

1 month / endpoints / Ayisha Sharma

Introducing the ESGO 2026 Social Media Ambassador Team

2 months / oncodaily

Kimryn Rathmell Welcomes Alex Bates as the New Director of Executive Communications for OSUCCC – James

2 months / oncodaily

Providing Essential Medicines for Children With Cancer in El Salvador – ACT 4 Children

2 months / oncodaily

Dean Crowe: Why Decisions about Infectious Diseases Policy Shouldn’t Slow mRNA Cancer Research

2 months / oncodaily

Developing National Cancer Control Plans in LMICs – NCI Center for Global Health

2 months / oncodaily

Aktis' 25% IPO bounce builds hope for 2026's public offerings

2 months / endpoints / Kyle LaHucik

Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals

2 months / medcitynews / Frank Vinluan

Saturday, January 10, 2026, 10:21 am / permalink 17733 / 8 stories in 2 months


FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndrome / Endpoints

Ayisha Sharma / endpoints - Corcept Therapeutics failed to secure US approval for its drug candidate as a hormonal disorder treatment. The FDA rejected Corcept’s selective cortisol modulator relacorilant for Cushing’s syndrome, according to a company

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

FDA rejects cortisol modulator for hypertension

2 months / beckershospitalreview / Ella Jeffries

FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndrome

2 months / endpoints / Ayisha Sharma

Monday, January 5, 2026, 1:21 am / permalink 17484 / 2 stories in 2 months


Low-dose peanut therapy shown to protect children with peanut allergies / Medical Express

medicalxpress - Children with peanut allergies may not need large doses of peanut oral immunotherapy (OIT) to build protection against peanuts, finds a new study led by The Hospital for Sick Children (SickKids) and Montreal Children's Hospital.

#healthcare #publichealth #biotech #drugdevelopment

Woman hospitalised over dessert containing nuts

7 wks / bbc

Lower Doses of Peanut Immunotherapy Could Make Allergy Treatment More Accessible

2 months / discovermagazine

Low-dose peanut therapy shown to protect children with peanut allergies

2 months / medicalxpress

Saturday, January 3, 2026, 5:21 pm / permalink 17464 / 3 stories in 2 months


Intratumoral Bacterial Burden Drives Immunotherapy Resistance in Head and Neck Cancer / OncoDaily

oncodaily - Immune checkpoint blockade (ICB) benefits only a subset of patients with head and neck squamous cell carcinoma (HNSCC), and commonly used biomarkers (PD-L1, TMB) remain imperfect in this setting. This […]

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN

2 months / esmo

NIVOPOST-OP Trial: Postoperative Nivolumab Plus Cisplatin-Based Chemoradiotherapy in High-Risk Locally Advanced Head and Neck Squamous Cell Carcinoma

2 months / oncodaily

Harnessing the microbiome for cancer therapy

2 months / nature

David Sher: 2 Nature Cancer Papers on Tumor Bacterial Burden and Immunotherapy Response

2 months / oncodaily

Global Incidence of Lip, Oral Cavity, and Pharyngeal Cancers – American Cancer Society Journals

2 months / oncodaily

Intratumoral Bacterial Burden Drives Immunotherapy Resistance in Head and Neck Cancer

2 months / oncodaily

Tumor bacteria linked to immunotherapy resistance in head and neck cancer

2 months / medicalxpress

Saturday, January 3, 2026, 11:20 am / permalink 17458 / 7 stories in 2 months


AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer / Endpoints

Ayisha Sharma / endpoints - AstraZeneca is spending $100 million upfront to secure ex-China rights for an early-stage cancer drug developed by Jacobio Pharma. The UK drugmaker will be responsible for advancing and selling the oral pan-KRAS inhibitor, JAB-23E73, in ...

#pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment

Nelson Dusetti: Why Oncogenic KRAS Alone Is Not Sufficient to Drive Pancreatic Cancer?

2 months / oncodaily

BridgeBio shares KRAS data; Hutchmed's Phase 3 success in China

2 months / endpoints / ENDPOINTS

Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial

2 months / nature / Benjamin L. Musher

Verastem axes Phase 1/2 lung cancer trial of Avmapki, pivots to KRAS blocker

2 months / endpoints / Ayisha Sharma

Naoto T. Ueno: Breakthrough Advances in K-RAS Inhibitor Development

2 months / oncodaily

Jacobio Pharma and AstraZeneca Strike $2 B Deal for Pan‑KRAS Inhibitor

2 months / oncodaily

AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer

2 months / endpoints / Ayisha Sharma

Saturday, December 27, 2025, 6:20 am / permalink 17306 / 7 stories in 2 months


Sanofi buys hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drug / Endpoints

Elizabeth Cairns / endpoints - Sanofi is set to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday. Separately, Sanofi said the ...

#healthcare #pharmaceuticals #publichealth #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #vaccinesafety

A One Health trial design to accelerate Lassa fever vaccines

2 months / nature / David Simons

Sanofi’s Vaccine Lineup Gets a Shot in the Arm With $2.2B Dynavax Acquisition

2 months / medcitynews / Frank Vinluan

Sanofi buys hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drug

2 months / endpoints / Elizabeth Cairns

Saturday, December 27, 2025, 2:21 am / permalink 17302 / 3 stories in 2 months


Back to Top


DRUGDEVELOPMENT Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...

FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...


NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.